Researchers sought to determine whether clinical and ultrasound assessment tools generally agree in their determinations of joint health for children with hemophilia on prophylaxis.
Treatment options for Hemophilia A including factors and other biologics.
Researchers showed there was a correlation between 2 methods of scoring hemophilic arthropathy in pediatric patients with hemophilia.
Researchers sought to determine whether patients with moderate or severe hemophilia A may benefit from early prophylactic antihemophilic factor (recombinant).
Researchers showed that adult men with hemophilia B had annual health care costs that totaled more than 25-fold higher than matched controls.
Researchers sought to determine whether using BAY 94-9027 long-term was safe and effective in pediatric patients with severe hemophilia A.
Hemophilia is a bleeding disorder caused by a genetic mutation that is often inherited. Patients who are at risk and parents or caregivers of children at risk of hemophilia may need additional education about what causes hemophilia and how it is diagnosed and treated.
Researchers conducted 2 sets of literature reviews to determine whether the professional society recommendations for >50% factor levels during labor in patients with hemophilia was accurate.
Researchers sought to determine whether recombinant factor VIII-Fc fusion protein would have greater efficacy as prophylaxis therapy over emicizumab in patients with hemophilia A.
